concordance rate was compared between the PZ and TZ using chisquare tests.
INTRODUCTION AND OBJECTIVES:
Bladder cancer is the sixth most common cancer in the United States, but the most expensive from diagnosis to death. Costly surveillance and treatment can lead to financial toxicity (FT), an adverse financial condition as a consequence of the treatment of a disease. The purpose of this study is to define the prevalence of FT among patients with bladder cancer and identify causes for delay in care.
METHODS: Bladder cancer patients were identified from the University of North Carolina Health Registry/Cancer Survivorship Cohort (HR/CSC), which includes patient-reported data on FT. FT was defined at agreement with the following statement "you have to pay more for medical care than you can afford." Demographic characteristics and factors leading to delayed care were compared using Fisher's exact tests.
RESULTS: 144 bladder cancer patients were enrolled in HR/ CSC, of which 138 completed the baseline questionnaire. Median age was 66.9 years. 75% were male, 89% were white, and 66% had less than a college degree. Half of patients had a stage of cT2 or higher. Thirty-three participants overall (24%) endorsed FT. Participants with FT were more likely to be younger, black, and have less than a college degree (p<0.01). Patients with non-invasive disease were more likely to report FT than those with invasive bladder cancer (15% vs. 30%; p¼0.04). Patients who endorsed FT were more likely to report delaying care (19.8% vs. 35 .1%) although this did not reach statistical significance (p¼0.07). Patients reporting FT were more likely to delay care due to inability to take time off work (p¼0.04) and inability to afford general expenses (p¼0.04).
CONCLUSIONS: FT is a major concern among bladder cancer patients, with nearly 25% reporting that healthcare costs are more than they could afford. Younger patients were more likely to experience FT, which may be related to Medicare eligibility at age 65, which increases affordability of care. Higher rates of FT among non-invasive disease may reflect long-term, costly surveillance.
Source of Funding: none

MP04-02 LONG TERM INCIDENCE OF VENOUS THROMBOEMBOLIC EVENTS FOLLOWING CYSTECTOMY: A POPULATION-BASED ANALYSIS.
Christopher Wallis*, Diana Magee, Raj Satkunasivam, Robert Nam, Toronto, Canada INTRODUCTION AND OBJECTIVES: Cancer and immobility both contribute to the development of venous thromboembolic events (VTE), including pulmonary embolism and deep vein thrombosis. As such, patients undergoing radical cystectomy for bladder cancer are at elevated risk. We sought to assess the long-term incidence of VTE among all patients undergoing radical cystectomy in the province of Ontario.
METHODS: We conducted a population-based cohort study to examine the incidence of VTE, a composite of pulmonary embolism and deep vein thrombosis, among all patients treated with radical cystectomy for bladder cancer between 2002 and 2014 in Ontario, Canada. We estimated the cumulative incidence of VTE and used Fine and Grey competing risk survival analysis to assess risk factors for VTE while accounting for the risk of any cause mortality. RESULTS: Among 3623 eligible patients, the 10 year cumulative incidence of VTE was 6.68% ( Figure) . Among those who experienced VTE, the median time from surgery was 216 days (interquartile range 52-677 days; mean 527 days). However, VTE rates peaked much earlier with a mode of 20 days. Neither preoperative (HR 0.68, 95% CI 0.39-1.18) nor postoperative chemotherapy (HR 1.32, 95% CI 0.95-1.84) were significantly associated with VTE incidence. While patients with a prior history of VTE had increased risk of VTE after cystectomy (HR 5.1, 95% CI 2.2-12.0), age, gender, comorbidity score, rurality, diversion type (continent vs ileal conduit), treatment at an academic institution, or year of treatment were not significantly associated with the risk of VTE.
CONCLUSIONS: Among patients undergoing cystectomy for bladder cancer, the cumulative incidence of VTE continues to rise long after the date of surgery indicating that previous studies may have underestimated these rates, but the highest rates occur at 20 days after surgery. Chemotherapy does not appear to increase the risk of VTE. METHODS: We identified 325 Medicare beneficiaries diagnosed with NMIBC between initial and 2-year follow-up using SEER-MHOS data (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) . NMIBC patients who underwent cystoscopy with biopsy or transurethral resection of bladder tumor(s) for bladder cancer were propensity matched 1:5 to non-cancer controls (n¼1685). Changes from baseline in the physical component score (PCS) and mental component score (MCS), which are normalized to between 0-100, where 50 represents the US population mean, were compared between NMIBC patients and non-cancer controls with c 2 testing and multivariate linear regression analysis. We secondarily assessed differences in urinary symptoms on post-diagnosis surveys with univariate and multivariate models.
RESULTS: Pre-diagnosis, mean PCS (39.94 vs 39.54, p ¼ 0.71) and mean MCS (52.03 vs 52.17, p ¼ 0.82) scores were similar between NMIBC patients and matched non-cancer controls. Postdiagnosis, NMIBC patients had a significantly greater decrease in PCS compared with controls (-2.87 (95% CI -3.87, -1.86) vs. -1.47 (95% CI -1.93, -1.02), p ¼ 0.02). Conversely, mean MCS change did not vary between groups (-1.79 (95% CI -2.76, -0.81) vs. -0.72 (95% CI -1.21, -0.23), p ¼ 0.09). With respect to urinary function, NMIBC pts were more likely to have worsening of urinary leakage (38.0 % vs 18.7 %, p¼ < 0.01), require physician intervention for urinary symptoms (33.9 % vs 13.7 %, p¼ <0.01 ), and receive treatment for urine leakage (31.6 % vs 12.0 %, p¼ <0.01 ) compared with non-cancer controls (p ¼ <0.01).
CONCLUSIONS: The diagnosis of NMIBC is associated with a significant decrease in physical HRQOL, including a significant impact on urinary symptoms and leakage. Further efforts to prospectively evaluate HRQOL in patients with NMIBC should be pursued to inform and improve patient counseling.
Source of Funding: none
MP04-04 CHARACTERIZING THE COSTS OF COMPLICATIONS AFTER CYSTECTOMY: CAN WE TARGET THE PRIMARY DRIVERS?
Matthew Mossanen*, Ross E. Krasnow, Matthew D. Ingham, Mark A. Preston, Quoc D. Trinh, Adam S. Kibel, Boston, MA; Steven I. Chung, Stanford, CA; Steven L. Chang, Boston, MA INTRODUCTION AND OBJECTIVES: Radical Cystectomy (RC) is subject to substantial morbidity and patients face complication rates as high as 64% at 90-days. Understanding the costs of complications after RC is essential to improving care. We studied the financial costs of different categories of complications after RC in order to identify drivers of expenditures.
METHODS: Using the Premier Hospital Database we identified adult patients who underwent RC for bladder cancer from over 600 hospitals across the United States between 2003-2013. Ninety-day complications were captured using ICD9 codes. Complications were categorized according to Agency for Healthcare Research and Quality Clinical Classification Software. The primary outcome was cost of complication and secondary outcomes were mortality, length of stay (LOS), and discharge disposition. A generalized liner model conforming to a gamma distribution was used to evaluate cost data. Analyses were survey weighted, and all models were adjusted for patient (age, race, obesity, marital status, payer), hospital (bed size, teaching affiliation, rural, region), and surgery characteristics (lymphadenectomy, continent diversion, robotic, operative time, transfusion, surgeon volume, hospital volume) and clustered by hospital.
RESULTS: We identified 9,137 RC patients, representing a weighting population of 57,553 patients. The top four most costly complications were venous thromboembolism (VTE $17547), soft tissue ($13523), gastrointestinal (GI $8663), and infectious (non-wound, i.e. sepsis, $7930) (p<0.001 for each). Pharmacy related costs were the primary driver of VTE costs. LOS was increased in each complication by 1.7 days for infectious, 4.5 days for soft tissue, 3.5 days for GI, and 3 days for VTE (p<0.001 for each). Being married, having fewer comorbidities, larger hospitals, teaching hospitals, shorter operations, lack of transfusions, high volume hospitals, and high volume surgeons were associated with statistically significantly lower costs of complications after cystectomy.
CONCLUSIONS: VTE, soft tissue, and GI complications are the most expensive complications after cystectomy, and thereby highlight potential candidates for future quality improvement initiatives.
Source of Funding: None
MP04-05 DECLINING USE OF CONTINENT DIVERSIONS FOR BLADDER CANCER
INTRODUCTION AND OBJECTIVES: Radical cystectomy with urinary diversion is a standard treatment for high-risk non-invasive and muscle-invasive bladder cancer. Continent diversions (CD) may allow better quality of life and body image perceptions over ileal conduits (IC) in selected patients. Our aim is to study contemporary trends in the utilization of ICs and CDs in patients undergoing radical cystectomy.
METHODS: Using ICD-9 codes, we identified in the National Inpatient Sample (NIS) from 2001-2012 all patients with the principal diagnosis of malignant neoplasm of bladder (188.x, 233.7) who underwent radical cystectomy (57.71) followed by either ileal conduit (56.61) or orthotopic neobladder/continent diversion (57.87). Patient sociodemographics, comorbidities and in-hospital complications,
